Phase IIa diabetes study termination

We have succesfully finished clinical part of phase II study with patients suffered from diabetes type II.
The aim of the study was to assess safety and efficacy of oral administration of IMP (different doses for each arm including placebo) accompanied to standard treatment, once daily for 14 consecutive days. 80 patients in total were enrolled. No drug related serious adverse events were recorded.

Go back


Christmas wishes

To all our Sponsors, partners, subcontractors and co-workers we would like to wish joyful Christmas and a Happy New Year!

Read more …

Participation in NCBiR project

As a Clinical Site we have won a tender for an innovative 1st phase project co-funded by NCBiR.

Read more …

GMP Specialist

Ms Dorota Osińska, M.Sc., Pharmacist, QP and experienced auditor, joined BioResearch and started GMP certification process.

Read more …

New Clinical Site

We have moved to our new Clinical Site, located in Kajetany, near Warsaw, where 1st phase, BQ and BA studies will be conducted.

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.


scroll to top ▲